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0022-2836/© 2008 Elsevier Ltd. Open accThe Nek family of serine/threonine kinases regulates centrosome and cilia
function; in addition, several of its members are potential targets for drug
discovery. Nek2 is dimeric, is cell cycle regulated and functions in the
separation of centrosomes at G2/M. Here, we report the crystal structures of
wild-type human Nek2 kinase domain bound to ADP at 1.55-Å resolution
and T175A mutant in apo form as well as that bound to a non-hydrolyzable
ATP analog. These show that regions of the Nek2 structure around the
nucleotide-binding site can adopt several different but well-defined
conformations. None of the conformations was the same as that observed
for the previously reported inhibitor-bound structure, and the two nucleo-
tides stabilized two conformations. The structures suggest mechanisms for
the auto-inhibition of Nek2 that we have tested by mutagenesis. Com-
parison of the structures with Aurora-A and Cdk2 gives insight into the
structural mechanism of Nek2 activation. The production of specific
inhibitors that target individual kinases of the human genome is an urgent
challenge in drug discovery, and Nek2 is especially promising as a cancer
target. We not only identify potential challenges to the task of producing
Nek2 inhibitors but also propose that the conformational variability
provides an opportunity for the design of Nek2 selective inhibitors because
one of the conformations may provide a unique target.© 2008 Elsevier Ltd. Open access under CC BY license.Keywords: Nek2 kinase; cancer; X-ray crystallography; structure-based drug
designEdited by G. SchulzIntroduction
The Nek family of serine/threonine kinases func-
tions in cell cycle regulation (reviewed by O'Regan
et al.1). The first member of this family, NIMA (never
in mitosis A) kinase, was identified in a genetic
screen and is an essential gene for entry into mitosis
in Aspergillus nidulans.2 There are 11 kinases related
to NIMA in the human genome, including Nek2,
Nek6, Nek7 and Nek9, which are mitotic regu-
lators.1 Nek2 has the highest sequence homology to
the fungal NIMA kinase, although RNA interference
knockdown of Nek2 does not significantly affect
mitotic entry.3 Instead, the role of Nek2 is to initiate
the separation of centrosomes at G2/M by phos-
phorylation of two components of the intercentriolaress:
ess under CC BY license.linkage, rootletin and C-Nap1.4–6 Nek2 is over-
expressed in several cancer cell lines and primary
breast cancers and has been identified as a potential
drug target in cholangiocarcinoma.7–10 Nek2
dimerizes through a C-terminal coiled-coil domain
that is essential for efficient cellular activity11 and
is activated by phosphorylation on its activation
loop at T175, which is reversed by PP1-mediated
dephosphorylation.12–14
Although the structures of surprisingly few
kinases have been captured in both active and inac-
tive conformations, comparisons of these structures
have identified the motifs that change conformation
upon activation.15,16 The DFG and HRD motifs are
highly conserved and contain catalytically vital
aspartic acid residues. The activation loop is imme-
diately C-terminal to the DFG motif, contributes to
substrate binding and helps organize other motifs.
The C-helix contains a conserved glutamic acid that
forms a salt bridge with a conserved lysine residue
477Flexibility and Regulation of Nek2 Kinasewithin the nucleotide-binding cleft. Formation of
this salt bridge is crucial for efficient catalysis.15
Many serine/threonine protein kinases are posi-
tively regulated by phosphorylation on their acti-
vation loop, and this event can help order the
surrounding motifs through electrostatic inter-
actions with arginines and/or lysines, particularly
the conserved arginine of the HRD motif, an
arginine/lysine on the activation loop (e.g., PKA)
or the C-helix (e.g., Aurora-A). Phosphorylation is
not sufficient to order the activation loop in some
kinases that also require the binding of additional
proteins, such as cyclins in the case of CDKs and
TPX2 in the case of Aurora-A.17,18 These additional
proteins bridge between the C-helix and the activa-
tion loop and promote an ordered active conforma-
tion of both elements of the kinase structure. In the
case of CDKs, the partner cyclin is required to move
the C-helix into an active conformation, whereas in
the case of Aurora-A, the C-helix is constitutively in
the active conformation and the partner TPX2
instead locks the activation loop into the active
conformation. Interactions at the C-helix can also be
inhibitory, as is the case for the Src family of tyrosine
kinases, where an N-terminal SH3 domain and
linker form an auto-inhibitory interaction that locks
the C-helix into an inactive conformation remini-
scent of inactive CDKs.19,20
Protein kinases are a major target for drug dis-
covery programs, and several kinase inhibitors are
now in routine use in the clinic.21 Most of these bind
the nucleotide-binding cleft of the kinase, competing
with ATP. Because there are more than 500 human
kinases, all of which are similar around the nucleo-
tide-binding cleft, the development of inhibitors that
are potent against only one or a few kinases is a
considerable challenge.22 The enzymatic activity of
kinases is highly regulated. Structurally, this arises
from at least two conformations of the kinase,
enzymatically active or enzymatically inactive.23,24
It is more challenging to develop specific inhibitors
that target the active kinase conformation (type I
inhibitors) because kinases exhibit very similar
active conformations with chemically similar
nucleotide-binding clefts, although there are notable
successes, such as PKB inhibitors.25 By contrast,
structures of inactive kinases adopt diverse con-
formations, and the design of inhibitors that target
inactive kinase conformations (type II inhibitors) is
now well established.26 One drawback of targeting
the inactive conformation is that it may be more
likely that resistant mutations that do not affect the
activity of the kinase will emerge.
The structure of a T175A point mutant of the
human Nek2 kinase domain bound to the tyrosine
kinase inhibitor SU-11652 has been previously
solved at 2.2-Å resolution.12 In this structure, Nek2
adopts an inactive conformation that resembles the
inactive conformation of Cdk2 or EGFR. Here, we
describe further structures of Nek2 that show how
the conformation of the inactive kinase depends on
the bound ligand and give insights into the regu-
lation of activity.Results
The activation loop of Nek2 adopts several
well-defined conformations dependent on the
ligand bound to the nucleotide-binding cleft
We have solved the crystal structures of apo-
T175A Nek2 (Nek2-T175AApo), ATPγS-bound
T175A Nek2 (Nek2-T175AATPγS) and ADP-bound
wild-type Nek2 (Nek2ADP) kinase domains to 2.3,
2.4 and 1.55 Å, respectively. In this article, we refer to
the previously solved structure of Nek2 bound to
SU-116592 as Nek2-T175ASU. Overall, the electron
density for all three new structures is excellent, and
regions where the structures differed could be
modeled with confidence (Fig. 1). Nek2-T175AATPγS
is the most complete model, with only 8 of the 271
residues missing. The other two structures have 13
and 16 residues missing (Table 1).
The four structures exhibit overall very similar con-
formations (overall pairwise Cα RMSD=0.20–0.95 Å;
Fig. 2a). The most striking differences are located in
the activation loop. Residues 167–178 form an α-
helix in Nek2-T175AATPγS, Nek2ADP and Nek2-
T175AApo but are disordered in Nek2-T175ASU.
The mutation of T175 to alanine does not affect the
structure of this helix; in addition, as this residue is
not involved in any side-chain interactions in its
unphosphorylated state, the mutation does not
influence the structure. Strikingly, the region from
residue 158 to residue 166, including the DFG motif
(159–161) and part of the activation loop, adopts a
completely different conformation in the Nek2-
T175AATPγS, Nek2ADP and Nek2-T175ASU struc-
tures (pairwise Cα RMSD=2.8–4.5 Å; Fig. 2b–d).
Nek2-T175AApo and Nek2-T175AATPγS are similar
in this region, although the electron density for
Nek2-T175AApo is weaker and the B-factors are
higher, suggesting that this region is less well
ordered in the apo kinase than in a ligand-bound
kinase (Figs. 1c and 2d). In Nek2-T175ASU, this
region forms an α-helix (αT) starting at D159,
whereas in the other structures, the helical con-
formation starts at F160 or G161 and is a 310-helix in
Nek2-T175AApo and Nek2-T175AATPγS (summar-
ized in Fig. 2e). All four structures superpose
precisely at L157 and begin to diverge at G158. At
D159, there is an approximately 180° difference in
the orientation of the side chain between Nek2ADP
and Nek2-T175AATPγS (Fig. 2b and f). In Nek2-
T175AATPγS, the D159 side chain sits close to the
HRD motif and forms hydrogen bonds with the
main chains of D141 and G161 (Fig. 1a), whereas in
Nek2ADP, the hydrogen bond is made with the side
chain of K37. The side chain of F160 also shows a
180° flip between Nek2ADP and Nek2-T175AATPγS.
In fact, F160 in Nek2ADP has an orientation similar
to D159 in Nek2-T175AATPγS and F160 in Nek2-
T175AATPγS has an orientation similar to D159 in
Nek2ADP (Fig. 2f). F160 in Nek2ADP sits close to the
main chain of the HRD motif and interacts with the
hydrophobic portion of the R164 side chain and the
Fig. 1. Electron density maps at the DFG and HRD motifs of Nek2. (a–c) 2mFo−DFc (gray) and mFo−DFc (green, red)
SigmaA-weighted electron density maps contoured at 1.0σ, 2.5σ and −2.5σ around (a) Nek2-T175AATPγS, (b) Nek2ADP
and (c) Nek2-T175AApo, respectively. Carbon atoms are shown in yellow, orange and pale pink in (a), (b) and (c),
respectively. Oxygen atoms are shown in red, whereas nitrogen atoms are shown in blue. The same color scheme for stick
representation is used in subsequent figures.
478 Flexibility and Regulation of Nek2 KinaseI165 side chain (Fig. 1b). F160 in Nek2-T175AATPγS
packs against K37, L162, I84 and M86. It is
remarkable that either of the D159 and F160 side
chains can be accommodated in these two positions.
In Nek2-T175ASU, these two side chains occupy yet
another set of positions (Fig. 2f). The orientation of
the D159 side chain in Nek2-T175ASU is roughlyhalfway between that observed in the other two
structures and forms a hydrogen bondwith the L162
main chain. This hydrogen bond caps and presum-
ably stabilizes the αT helix. In Nek2-T175ASU, the
HRD motif is disordered and the side chain of F160
in Nek2-T175ASU lies in the path followed by the
main chain of the HRD motif in the other Nek2
Table 1. Summary of crystallographic analysis
Nek2ADP Nek2-T175AATPγS Nek2-T175AApo
Crystals
Space group C2 C2 C2
Lattice constants
a (Å) 99.47 99.60 99.74
b (Å) 57.10 57.06 56.96
c (Å) 80.21 80.80 80.61
β (°) 132.99 133.45 133.36
Data collection
X-ray source European Synchrotron
Radiation Facility 14.2
European Synchrotron
Radiation Facility 14.1
DIAMOND I03
Resolution range (Å)
(highest-resolution
shell values)
26.23–1.55 (1.63–1.55) 49–2.40 (2.53–2.40) 58.6–2.33 (2.46–2.33)
Unique reflections 45,663 (5161) 12,943 (1884) 12,969 (1453)
Completeness (%) 95.6 (74.5) 99.2 (99.2) 91.3 (72.3)
Multiplicity 3.6 (2.8) 2.5 (2.5) 3.7 (3.6)
Rmerge (%) 4.8 (32.4) 9.7 (19.9) 10.8 (35.9)
I/σ(I) 15.8 (3.1) 3.9 (2.9) 6.1 (2.0)
Refinement
Resolution range (Å) 24.74–1.55 49–2.40 58.6–2.33
No. of amino acids 266 271 263
No. of water molecules 355 166 120
No. of Mg ions 1 1 –
No. of Cl ions – 1 –
No. of ethylene glycol molecules 4 – –
Name of ligand bound to active site ADP ATPγS –
R-factor (%) 17.21 18.3 19.5
Rfree
a (%) 19.01 24.5 25.4
Ramachandran plot (%)
Most favored 91.5 90.9 91.4
Allowed 8.5 9.1 8.6
Generously allowed 0.0 0.0 0.0
Forbidden 0.0 0.0 0.0
a Free R-factor was computed using 5% of the data assigned randomly and is the same for all three structures.27
479Flexibility and Regulation of Nek2 Kinasestructures and packs against L157, L124 and L142.
None of the positions occupied by D159 and F160 in
these three structures is what would be expected in
an active conformation (Fig. 2f). In other words,
Nek2 exhibits three examples of so-called DFG-out
conformations. Indeed, the pocket that would be
occupied by F160 in the active conformation is
unoccupied in three of the structures and by an
ethylene glycol molecule from the cryoprotectant
in Nek2ADP. D159 is a minimum of 90° away
from its position in an active conformation in all
four structures. L162 from Nek2ADP and Nek2-
T175AATPγS/Nek2-T175AApo fits into a pocket
formed from L52, E55 and L59 of the C-helix and
I83. In Nek2-T175ASU, the side chain of I165 fits into
the equivalent pocket. The R164 side chain forms
different contacts in all three structures and adopts
very different positions. R164 interacts with H139 in
Nek2-T175AATPγS, with the β-phosphate of ADP in
Nek2ADP and with E55 in Nek2-T175ASU.
The region of the activation loop proximal to the
DFG motif has been proposed to form an inhibitory
helix (αT; Fig. 2a and c).12 If this were a feature of the
inactive conformation that required unfolding for
activity, then one would predict that disruption of
the secondary structure would increase the activity
of the kinase. We made an A163G mutation in theactivation loop to disrupt the secondary structure
and tested the activity of the mutant kinase (Fig. 3a).
This mutation reduced the activity of the kinase to
the same extent as a mutation in a catalytic residue
(K37) or regulatory residue (S241).12 Thus, it is
unlikely that conversion from the inactive to the
active conformation relies purely on unfolding of
this putative inhibitory helix.
Coordination of nucleotide
In common with other protein kinase structures,
the nucleotide sits in the active-site cleft of Nek2
between the Gly-rich loop and β7/β8. The position-
ing of the nucleotide within the cleft resembles that
found in other inactive kinase structures, in which
the phosphates lie closer to the solvent-exposed side
of the pocket than is observed in kinase active
conformations. This is illustrated in Fig. 4a, where
the nucleotides bound to active Aurora-A and Cdk2
are shown in magenta and blue, respectively,
compared with inactive Cdk2 and Nek2, which are
shown in cyan and yellow, respectively.
Both ADP and ATPγS are bound in the active-site
pocket by a network of hydrogen bonds, electro-
static interactions and hydrophobic contacts (Fig. 4b
and c). Most of these interactions are identical bet-
480 Flexibility and Regulation of Nek2 Kinaseween the Nek2ADP and Nek2-T175AATPγS struc-
tures. The hinge region of Nek2 forms two hydrogen
bonds with the adenine base, the main-chain oxygen
of Glu87 is an acceptor and the main-chain nitrogen
of Cys89 is a donor. A network of water molecules
links the adenine N3 and the ribose 2′ hydroxyl with
the main-chain nitrogens of Gly92 and Asp93 and
the Asp93 side chain. The Gly-rich loop (amino acids
15–20) contacts nucleotide phosphates directly
through water molecules. A single magnesium ion
bridges the α- and β-phosphates and bridges to theFig. 2. The DFG motif and activation loop adopt
different conformations dependent on the bound ligand.
(a) Superposition of Nek2-T175AATPγS (yellow), Nek2ADP
(orange) and Nek2-T175ASU (green) protein structures
shown as a ribbon in two orientations related by a 90°
rotation about the y-axis. (b) Stereoview of Nek2-
T175AATPγS (yellow carbon atoms) and Nek2ADP
(orange carbon atoms) superposition at the DFG motif.
(c) Stereoview of Nek2-T175AATPγS (yellow carbon atoms)
and Nek2-T175ASU (green carbon atoms) superposition at
theDFGmotif. (d) Stereoview ofNek2-T175AATPγS (yellow
carbon atoms) and Nek2-T175AApo (light pink carbon
atoms) superposition at the DFGmotif. (e) Schematic of the
secondary structures adopted by the four Nek2 structures
and the amino acid sequence surrounding the DFG motif
in Nek2 and Aurora-A. (f) Superposition of three Nek2
conformations of the DFG motif together with the likely
position adopted in the fully active conformation based on
the Aurora-A/TPX2 structure (magenta). The orientation
is that of panels (b) to (d) viewed from the bottom left to the
top right.main chain of the DFG motif through water
molecules. A clear difference between the Nek2ADP
and Nek2-T175AATPγS protein structures is the
interactions formed by Arg164. In Nek2ADP, it
forms a salt bridge with the β-phosphate of ADP,
whereas in Nek2-T175AATPγS, it interacts with
Asp159 of the DFG motif (Figs. 2 and 4c).
A crystal contact that resembles a hydrophobic
plug forms an auto-inhibitory motif
In the three Nek2 structures described in this
article, the activation loop forms a crystal contact
with a hydrophobic groove between the C-helix and
β4/β5 strands of an adjacent molecule (Fig. 5a). This
contact bears a striking resemblance to the hydro-
phobic groove–hydrophobic plug interaction
involved in AGC (protein kinases A, G and C) and
Aurora kinase regulation (Fig. 5b, reviewed by Gold
et al.28). The side chains of F172sym and F176sym pack
into the hydrophobic groove. There are also inter-
actions between D179sym and R60/R79 and between
the main chain of A176sym and R77. There is no
other crystal contact involving the C-helix. A key
role for the hydrophobic plug is to increase the
stability of the kinase, essentially by completing the
hydrophobic core of the N-lobe (reviewed by Gold et
al.28). Indeed, the crystal contact directs the ordering
of the C-helix of Nek2ADP and Nek2-T175AATPγS (all
side chains ordered) compared with Nek2-T175ASU
(7 of 18 side chains disordered), which does not have
the same crystal contact. The full-length Nek2
protein dimerizes through a C-terminal coiled-coil
domain.11 To investigate whether this crystal contact
might represent a physiological interaction in the
Nek2 dimer, we made mutants in the full-length
protein to disrupt the interface (F172A and F176A).
The mutations resulted in a three- to fourfold
increase in kinase activity, the effect opposite to
that expected if this interaction activated the kinase.
Moreover, because the crystal contact stabilizes an
inactive conformation of the C-helix, this suggests
Fig. 3. Mutations in the activation loop that increase or decrease Nek2 kinase activity. In vitro transcribed/translated
wild-type and mutant Nek2 proteins were immunoprecipitated and assayed for kinase activity. (a) Mutation in the
activation loop proximal to the DFG motif (A163G) or in the phospho-regulated residues (S241A, S241D) compared with
wild type (WT) and kinase-dead mutant (K37R). (b) Mutations in the hydrophobic plug motif (F172A and F176A)
compared with WT and K37R.
481Flexibility and Regulation of Nek2 Kinasethat the crystal contact may mimic an auto-
inhibitory interaction in the full-length protein.Discussion
Here, we describe three quite distinct structures of
the kinase domain of the cell cycle-regulated human
protein Nek2. When compared with the inhibitor-
bound structure, T175A-Nek2SU, the activation loop
exhibits a consistent difference in residues 167–178
influenced by crystal packing. The DFG motif and
proximal region (residues 158–166) can adopt three
conformations dependent on the ligand bound; in
the absence of ligand, this region is less well
ordered. This raises the question of how ligands
might direct the different conformations of the DFG
motif. One crucial difference between Nek2-
T175ASU and the other two ligand-bound structures
is that SU-116592 buries a hydrophobic moiety
deeper into the nucleotide-binding cleft. L162
forms a close van der Waals interaction with SU-
116592, whereas in the other Nek2 structures, L162
is buried into a pocket in the underside of the C-
helix. The SU-116592 ligand also prevents the
interaction between D159 and K37 and does not
present an alternative partner for K37. Instead, K37
forms a hydrogen bond with the side-chain hydro-
xyl of Y19, which adopts a rotamer that brings it
under the Gly-rich loop. The main difference
between the Nek2ADP and Nek2-T175AATPγS
protein–ligand contacts concerns R164, which inter-
acts with the β-phosphate of ADP but interacts with
the side chain of D159 in Nek2-T175AATPγS. InNek2ADP, D159 interacts with K37, and in both
structures, K37 interacts with the α-phosphate of the
nucleotide. The altered interactions of R164 and
D159 (within and immediately C-terminal to the
DFG motif) direct the altered conformation of the
main chain.
In Nek2-T175ASU, the DFG motif and five follow-
ing residues form an α-helix (αT), a feature that was
proposed to be an inhibitory motif requiring
unfolding in order to achieve the active conforma-
tion.12 The structures of Nek2 described in this
article show that this region can adopt one of several
conformations, and the precise conformation of the
kinase is sensitive to the ligand occupying the
nucleotide-binding cleft. Crucially, we found that
in the Nek2-T175AApo structure, the activation loop
appeared less ordered than in structures with ligand
bound, and we have also observed that this region is
disordered in apo-form crystals produced using
ADP co-crystals soaked for 24 h into an ADP-free
solution (data not shown). We conclude that much
of the Nek2 structure forms a rigid framework that
is characteristic of the inactive conformation, around
which the variable regions organize. The variable
regions include the DFG motif, activation loop and
HRD motif. It appears that these regions become
ordered by forming electrostatic interactions (e.g.,
E55, K37 and the ligand) and hydrophobic interac-
tions with available partners (e.g., L52/E55/L59
pocket, HRD motif and hydrophobic surfaces of the
ligand). That the rest of the structure is stable and
that the activation loop can readily adopt one of
several conformations call into question the assign-
ment of this region as being auto-inhibitory. More-
Fig. 5. A crystal contact in Nek2 makes a hydrophobic
plug–hydrophobic groove interaction. (a) Interactions at a
crystal contact between two Nek2 molecules shown as
yellow cartoon/stick for the hydrophobic groove-bearing
symmetry-related partner and as sticks (gray carbon
atoms) for the hydrophobic motif-bearing partner. (b)
The hydrophobic groove–hydrophobic plug interaction
between Aurora-A (magenta cartoon and carbon sticks)
and TPX2 (white carbon sticks). (c) Superposition of Nek2-
T175AATPγS (yellow), inactive Cdk2 (cyan) and cyclin-
bound Cdk2 (blue).
Fig. 4. Network of interactions that loosely bind
nucleotide to Nek2. (a) Superposition of nucleotide-
binding clefts of two inactive kinase conformations
[Nek2-T175AATPγS (yellow) and ATP-bound Cdk2 (cyan,
Protein Data Bank code 1B39)] and two active kinase
conformations [ADP-bound Aurora-A (magenta, Protein
Data Bank code 1OL5) and ATP-bound Cdk2 (blue,
Protein Data Bank code 1QMZ)]. (b) Structural represen-
tation of the interactions that bind ADP to inactive Nek2,
including water molecules (black crosses) and a magne-
sium ion (green cross). (c) Structural representation of the
interactions that bind ATPγS to inactive Nek2, including
water molecules (black crosses) and a magnesium ion
(green cross).
482 Flexibility and Regulation of Nek2 Kinaseover, mutations that disrupt the secondary structure
in this region do not activate the kinase but reduce
activity. Instead, it appears more likely that astructural element that is in a similar conformation
in all four structures presents a barrier to a fully
ordered structure and full activity. One candidate
structural element is the C-helix, which is displaced
from the position observed in active kinase con-
formations (Fig. 5c). Indeed, the C-helix adopts a
483Flexibility and Regulation of Nek2 Kinaseposition redolent of inactive Cdk2 and would
similarly require a rotation of approximately 90° to
move the catalytic glutamic acid (E55 in Nek2) into
the active position (Fig. 5c). How could this
structural transition occur? Although activation of
the kinase requires phosphorylation on T175, the
question remains as to whether this would be suffi-
cient to stabilize the active conformation. There is no
arginine or lysine residue in the C-helix in a suitable
position to coordinate with phospho-T175 and
direct its movement into an active position. Hence,
movement of the helix may require a binding
partner that bridges between the C-helix and the
activation loop, as is the case for Cdk2/cyclin. In
Nek2, this would involve the binding of a hydro-
phobic plug motif to the hydrophobic groove
located at the C-helix. The hydrophobic motif at
the crystal contact cannot fulfill this function and
instead appears to form an auto-inhibitory interac-
tion as demonstrated by the activating mutants
F172A and F176A. An alternative hydrophobic
motif partner may have to displace the F172/F176
motif, and this could result from a conformational
change in the dimeric, full-length protein or binding
of an additional protein factor. Further studies will
be required to investigate the requirement of a
hydrophobic motif–groove interaction for Nek2
regulation and the identity of the hydrophobic
motif donor.
The fact that the DFG motif and activation loop
can adopt several stable conformations is a possible
hurdle to the rapid production of inhibitors that
specifically target Nek2. For example, computa-
tional techniques, such as virtual screening, must be
able to handle the conformational variability of the
protein. Relatively small changes to hit compounds
might induce stabilization of a different conforma-
tion, confusing structure–activity relationship ana-
lyses. On the other hand, the variability might be
considered an opportunity as one of these con-
formations may provide the right template for a
selective Nek2 inhibitor. Inhibitors that target the
DFG-out conformation are perhaps the most pro-
mising in terms of selectivity.24 The conformation of
Nek2ADP most resembles the DFG-out conformation
of tyrosine kinases recognized by selective inhibi-
tors, such as imanitib, and there is a solvent-filled
channel that connects the ADP-binding site to a
hydrophobic pocket, occupied by an ethylene glycol
molecule, that would be filled by the DFG motif
phenylalanine in the active conformation. We pre-
dict that ligand–protein crystal structures will play a
central role in a Nek2 drug discovery program. This
endeavor will be greatly aided by our apo-form
crystals that grow in suitable conditions for soaking
experiments with a variety of ligands.
Another important consideration is whether it is
possible to predict which other kinases can adopt
multiple stable inactive DFG motif conformations.
Two notable features of Nek2 may explain why the
DFG motif can adopt very divergent conformations:
First, it has a glycine N-terminal to the DFG motif,
which is the point of divergence for the four Nek2structures. Less than 10% of human kinases have a
glycine in this position, giving rise to a low energetic
barrier to transitions between different conforma-
tions of the DFGmotif. This glycine residue has been
proposed as an important determinant of flexibility
by comparison of different tyrosine kinases, and the
structures we present demonstrate how this glycine
permits variability in different structures of the same
kinase.29 Second, the inactive position of the C-helix
leaves a large cavity for the activation loop, and the
C-helix also provides a hydrophobic surface (on the
underside of the hydrophobic groove) against which
a variety of hydrophobic side chains can pack.
Recently, more sophisticated computational ana-
lyses of kinase conformational states and activation
that use statistical analysis of kinase structures or
simulation have been presented.16,30 It would be a
significant step to combine these approaches with
high-throughput crystallography to assess the con-
formational space accessible to kinase inactive
states. Do some kinases have access to a wider
range of conformations for a functional reason, and
does this reflect the different regulatory mechanisms
of these kinases? Furthermore, this analysis should
be applied to a large number of kinases so that our
knowledge is not biased toward a few models. This
approach may be used to tackle the selectivity
problem in kinase drug discovery by the prediction
of specific inactive conformations of kinases that can
be targeted by small-molecule inhibitors.Methods
Protein expression and purification
The structure of the Nek2 kinase domain mutated at the
activating threonine, T175A, has previously been deter-
mined.12 The mutant kinase domain was used because the
wild-type kinase domain is insoluble and unstable. We
reasoned that since the T175A mutant is stably expressed,
the poor physicochemical properties of the wild-type
protein are due to excessive kinase activity and resultant
auto-phosphorylation. Co-expression of the wild-type
kinase with lambda phosphatase improved the solubility
properties, enabling the production of sufficient material
for crystallization.
The cloning of Nek2-T175A in pET22b has been
previously reported.12 Wild-type Nek2 was cloned into
the NdeI/XhoI sites of pET30, giving rise to the same
protein sequence as in pET22b, including an uncleavable
C-terminal His6 tag. Lambda phosphatase was cloned into
the NcoI/EcoRI sites of pCDF-Duet (Novagen). The
coding sequence of the plasmids was confirmed by
sequencing. Plasmids encoding either T175A-Nek2 or
wild-type Nek2 and lambda phosphatase were trans-
formed into CodonPlus RPIL Escherichia coli (Stratagene)
and were cultured at 37 °C to an A600 of 0.5. The
temperature was reduced to 18 °C for 30 min. Expression
was induced using 1 mM isopropyl β-D-1-thiogalacto-
pyranoside. Cells were harvested by centrifugation after
4 h and stored at −80 °C. For purification, a 2-l cell pellet
was resuspended in lysis buffer (50 mM Hepes, pH 7.5,
5 mM sodium phosphate, 300 mM sodium chloride, 5%
glycerol and 20 mM imidazole) and was lysed by
484 Flexibility and Regulation of Nek2 Kinasesonication. The lysate was loaded on a 1-ml HisTrap
column (GE Healthcare), and Nek2 was eluted using a 20–
250 mM imidazole gradient. Eluted Nek2 protein was
purified to homogeneity using a 16/60 Superdex S200
HiPrep column (GE Healthcare) equilibrated in 50 mM
Hepes, pH 7.5, 300 mM sodium chloride, 10 mM sodium
phosphate, 5 mM dithiothreitol and 5% glycerol. T175A-
Nek2 was treated with 40 μl of SAP (1 U/μl, USB) and
5 mMmagnesium chloride over 2–3 days. Purified protein
was concentrated to 5–8 mg/ml and was flash frozen in
10-μl aliquots. The protein was partially precipitated after
1 day at 4 °C. Protein that had been frozen crystallized
readily, and the resultant crystals diffracted well.
Crystallization of nucleotide-bound Nek2 wild type
and T175A
Crystals of Nek2 were produced by vapor diffusion
using the hanging-drop method. The well buffer used
contained 2%–10% PEG (polyethylene glycol) 8000 and
50 mM Tris, pH 8.5, mixed 1:1 with the concentrated
protein solution supplemented with 5mMADP and 5mM
magnesium sulfate for the ADP crystals, 5 mM ADP and
10% dimethylsulfoxide for the apo crystals and 5 mM
ATPγS for the ATPγS crystals. Drops were immediately
micro-seeded, and crystals grew to approximate dimen-
sions of 50 μm×20 μm×5 μm in 2 days. Harvested crystals
were briefly transferred to cryoprotectant (12% PEG 8000,
60 mM Tris, pH 8.5, and 28% ethylene glycol) and flash
frozen in liquid nitrogen. We also produced apo-form
crystals by soaking ADP crystals in well buffer solution
over 24 h.
Structure solution and refinement
X-ray diffraction data were integrated using Mosflm31
and scaled using SCALA.31 The structure of Nek2-
T175AATPγS was solved by PHASER31 using the Nek2-
T175ASU model. Nek2ADP and Nek2-T175AApo were
solved using Nek2ATPγS as the model. Structures were
refined using Phenix32 and built using Coot.31 TLS
refinement used a single group for Nek2-T175AATPγS
and Nek2-T175AApo, and eight groups were defined
using TLSMD33 for Nek2ADP. The final models com-
prised residues 3–131, 138–166, 171–191 and 193–271
(+8-residue tag) for Nek2ADP, residues 3–131 and 138–
271 (+8-residue tag) for Nek2-T175AATPγS and residues
3–131, 139–164, 168–189 and 192–271 (+8-residue tag) for
Nek2-T175AApo. Least-squares fitting used LSQKAB.31
Structure figures were produced using PyMOL (Warren L.
DeLano, “The PyMOL Molecular Graphics System,”
DeLano Scientific, San Carlos, CA, USA†). An active
Cdk2 model shown is 1QMZ; inactive, 1B39; and Aurora-
A/TPX2, 1OL5. Crystal structures of Nek2-T175AATPγS,
Nek2ADP and Nek2-T175AApo were used.
Mutagenesis and kinase assays
Mutations were introduced into the pRMCV-myc-
Nek2A plasmid using the Gene Tailor™ Site-Directed
Mutagenesis System (Invitrogen) and confirmed by DNA
sequencing (Lark Technologies). For in vitro kinase assays,
myc-Nek2A proteins were generated by coupled in vitro
transcription–translation reactions using the TnT kit†http://www.pymol.orgaccording to the manufacturer's instructions (Promega)
and then immunoprecipitated with anti-myc antibodies
and the immunoprecipitates used in kinase assays with β-
casein as substrate, as previously described.12
Accession codes
The coordinates of Nek2-T175AATPγS, Nek2ADP and
Nek2-T175AApo and their associated structure factors
have been deposited in the Protein Data Bank with
accession codes 2W5B, 2W5A and 2W5H, respectively.Acknowledgements
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